Risk of arteriovenous fistula failure associated with hypnotic use in hemodialysis patients: a nested case-control study

Chao Feng Lin, Hung Yi Chiou, Ya Hui Chang, Ju Chi Liu, Yen Ni Hung, Ming Tsang Chuang, Li Nien Chien

研究成果: 雜誌貢獻文章

1 引文 斯高帕斯(Scopus)


Purpose: Hypnotic use might cause altered inflammatory processes, which have been suggested as being related to the mechanisms of arteriovenous fistula (AVF) failure. Therefore, we examined the association between the risk of AVF failure and hypnotic use in patients receiving hemodialysis (HD). Methods: A nested case–control study was conducted using data from the National Health Insurance Research Database of Taiwan. From 34 165 HD patients, 3676 patients receiving percutaneous transluminal angioplasty or surgical thrombectomy for AVF failure were matched to 14 704 control patients according to sex, age (±1 year), and the year of initial HD therapy. The risk of AVF failure was estimated based on conditional logistic regression after adjustment for the timing of AVF creation, HD frequency, comorbidities, and prescribed medications. Hypnotic use was measured prior to the date of AVF failure of case patients and the date of pseudo-AVF failure of controls. Results: Compared with matched controls, case patients were more likely to be exposed to hypnotics 30 days or an average daily defined dose > 0.5 within 90 days before the date of AVF failure, with an adjusted odds ratio of 1.21 (95% confidence interval [CI]: 1.09–1.35, p < 0.001) and 1.36 (95%CI: 1.13–1.63, p = 0.001), respectively. Risk of AVF failure associated with hypnotic use was also observed among HD patients who were male, were younger than 65 years, had hypertension, and did not use statins. Conclusions: Hypnotic use among HD patients was associated with an increased risk of AVF failure.

頁(從 - 到)889-897
期刊Pharmacoepidemiology and Drug Safety
出版狀態已發佈 - 八月 1 2016


ASJC Scopus subject areas

  • Pharmacology (medical)
  • Epidemiology